Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

7 evidence topics · 5 sources

Distant-stage disease at diagnosis, all prostate cancer
SEER measureQuoted value
Percentage of cases diagnosed at distant stage“9%”